Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Foghorn Therapeutics Inc (FHTX)

Foghorn Therapeutics Inc (FHTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit GlobeNewswire - Tue Feb 3, 6:00AM CST

WATERTOWN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...

FHTX : 5.17 (-4.61%)
Hard-to-Treat Cancers: How 2026’s Top Clinical Platforms Are Beating Industry Benchmarks BayStreet.ca - Tue Jan 27, 9:45AM CST

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The global oncology market is charging toward a massive $668 billion valuation by 2034[1], fueled by a...

ONCY : 0.8337 (-2.32%)
FHTX : 5.17 (-4.61%)
ORIC : 10.09 (-1.08%)
LLY : 1,042.83 (+2.72%)
GOVX : 2.40 (-5.88%)
SLS : 3.52 (-4.09%)
Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium GlobeNewswire - Tue Jan 13, 3:05PM CST

WATERTOWN, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...

FHTX : 5.17 (-4.61%)
Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026 GlobeNewswire - Fri Jan 9, 9:20PM CST

Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a leading biotech mutual fund in a transaction that will close January 13 th , 2026 ...

FHTX : 5.17 (-4.61%)
Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference GlobeNewswire - Tue Nov 25, 2025

CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...

FHTX : 5.17 (-4.61%)
Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update GlobeNewswire - Wed Nov 5, 2025

Ongoing FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1)-mutated cancer remains on track with non-small cell lung cancer (NSCLC) as the primary target population  Selective CBP...

FHTX : 5.17 (-4.61%)
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences GlobeNewswire - Mon Nov 3, 2025

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...

FHTX : 5.17 (-4.61%)
Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs GlobeNewswire - Thu Oct 30, 2025

- Data presented at the TPD and Induced Proximity Summit demonstrate that novel Selective ARID1B degrader selectively binds and degrades ARID1B; potentially relevant in up to 5% of all solid tumors  ...

FHTX : 5.17 (-4.61%)
Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit GlobeNewswire - Thu Oct 16, 2025

CAMBRIDGE, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases...

FHTX : 5.17 (-4.61%)
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences GlobeNewswire - Wed Aug 27, 2025

CAMBRIDGE, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- August 27, 2025 -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat...

FHTX : 5.17 (-4.61%)

Barchart Exclusives

As Salesforce Acquires AI Startup Cimulate, Should You Buy, Sell, or Hold CRM Stock? Barchart - 10 minutes ago
Salesforce signed a deal to acquire Cimulate, an AI-powered product discovery startup. The acquisition strengthens Agentforce Commerce with better search and personalized shopping. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot